Periodontal Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Periodontal Disease Market Outlook

Thelansis’s “Periodontal Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Periodontal Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Periodontal Disease Overview

Periodontal disease activity is defined clinically by progressive loss of probing attachment and radiographically by progressive loss of alveolar bone. This disease, encompassing gingivitis, and periodontitis, exhibits high prevalence among adults, and its severity tends to increase with age. It is a bacterial infection primarily affecting the dental biofilm or plaque. Individual risk factors for periodontal disease can be categorized as follows: lifestyle factors such as gender, smoking, and alcohol; diabetes; obesity and metabolic syndrome; osteoporosis, dietary calcium, and vitamin D; stress; and genetic factors. The common signs and symptoms of periodontal disease include redness, swelling, and tenderness of the gums; bleeding during brushing and flossing; recession of the gums; loose or separating teeth; persistent halitosis; ill-fitting partial dentures; the presence of pus between the teeth and gums; and alterations in bite and jaw alignment. Periodontal disease is classified into different types based on disease stage, including gingivitis, mild periodontitis, and moderate to advanced periodontitis. Gingivitis represents the mildest form, characterized by red, swollen, and tender gums that bleed easily. Timely dental care and consistent home care can help resolve these issues. If left untreated, gingivitis progresses to mild periodontitis, where periodontal pockets form as the gums detach from the teeth, leading to early bone loss. Prompt dental intervention is necessary to prevent further bone erosion and gum damage. In the most advanced stage, moderate to advanced periodontitis, significant bone loss, deepening of periodontal pockets, and gum recession are observed. Extraction of teeth may be required due to tooth looseness. Treatment options for periodontal disease may include tartar and plaque removal below the gumline through deep cleaning (scaling and root planing), eliminating tartar and infected tissue in the early stages while smoothing damaged root surfaces to facilitate gum reattachment. Antibacterial medications can be applied topically in periodontal pockets or taken orally. In advanced cases, surgery may be necessary to clean infected areas beneath the gums and reshape or replace tissues.

• Data indicate that 47.2% of adults aged 30 years and older have some periodontal disease. Moreover, its prevalence increases with age, with 70.1% of adults aged 65 years and older affected.
• This condition exhibits higher occurrence among men compared to women (56.4% vs. 38.4%), individuals living below the federal poverty level (65.4%), those with less than a high school education (66.9%), and current smokers (64.2%).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: